Author

Marty Schladen

Marty Schladen

Marty Schladen has been a reporter for decades, working in Indiana, Texas and other places before returning to his native Ohio to work at The Columbus Dispatch in 2017 and coming to the Ohio Capital Journal in 2020. He's won state and national journalism awards for investigations into utility regulation, public corruption, the environment, prescription drug spending and other matters.

Biden administration plan to cut high drug prices mostly quiet on middlemen

By: - September 14, 2021

The U.S. Department of Health and Human Services last week issued a plan to address high drug prices as part of President Joe Biden’s push to take on anticompetitive practices across the economy. Although it addressed in detail abusive practices by drugmakers, the plan was more superficial about the practices of some of the country’s […]

With antitrust emerging as key concern on Capitol Hill, drug pricing comes to the fore

By: - June 2, 2021

Congress is beginning to take notice as corporations become increasingly dominant in one or more marketplaces. It’s investigating whether Amazon, Google, Apple and Facebook are engaging in anticompetitive practices. And Sen. Amy Klobuchar, D-Minn., just published a book about the need to revive the government’s antitrust powers. But if this is to be a new […]

Reports: Drug manufacturers and middlemen both responsible for rising prices

By: - May 19, 2021

The world of prescription drug pricing can be bewildering — intentionally so, some critics of the industry claim.  Whether that’s true or not, several reports this year show that the supply chain’s alchemy of list prices, rebates and net prices hurts consumers. And a U.S. Senate report says drugmakers and middlemen share the blame. The […]

Federal probe of drug middlemen urged

By: - May 11, 2021

After years of accusations in Minnesota and elsewhere, a bipartisan group in the U.S. Senate wants federal regulators to investigate whether drug middlemen and their parent companies are rigging the system to raise prices and pad their pockets. Sens. Chuck Grassley, R-Iowa, and Maria Cantwell, D-Wash., last month filed legislation that would require the Federal Trade Commission […]

Big fight over drug pricing with implications for Minnesota heads to the Supreme Court

By: - October 6, 2020

A years-long fight over whether states have the authority to regulate important aspects of drug pricing will be argued before the U.S. Supreme Court Tuesday morning. At issue is whether prescription middlemen, known as “pharmacy benefit managers,” will have to bow to state authority over a huge swath of their business or if federal law […]

‘14,000 attempts.’ Balky technology, expiring benefits worry workers, state leaders

By: - July 31, 2020

Congress is continuing to squabble over whether to extend a federal supplement to unemployment insurance and if they do, by how much. But as they argue over whether to continue the supplement at $600 a week or some fraction of that, out-of-work Americans are left to worry whether they can survive on state benefits that […]